Full Text
REGD. No. D. L.-33004/99
The Gazette of India
CG-DL-E-28112025-268071
EXTRAORDINARY
PART II-Section 3-Sub-section (ii)
PUBLISHED BY AUTHORITY
No. 5295]
NEW DELHI, FRIDAY, NOVEMBER 28, 2025/AGRAHAYANA 7, 1947
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 28th November, 2025
S.O. 5476(E). — In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)
Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the
Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority
(hereinafter referred as NPPA) hereby fixes, the price as specified in column (6) of the table herein below as the retail price,
exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column
(2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the
corresponding entries in columns (3), (4) and (5) thereof;
TABLE
+-----+-------------------------+------------------------------------------------------------------------------------+----------+-----------------------------------+-------------+
| SI. | Name of the | Strength | Unit | Manufacturer & | Retail |
| No. | Formulation / | | | Marketing Company | Price |
| | Brand Name | | | | (Rs.) |
+-----+-------------------------+------------------------------------------------------------------------------------+----------+-----------------------------------+-------------+
| (1) | (2) | (3) | (4) | (5) | (6) |
+-----+-------------------------+------------------------------------------------------------------------------------+----------+-----------------------------------+-------------+
| 1 | Bisoprolol Fumarate | Each uncoated bilayered tablet | 1 Tablet | M/s Windlas Biotech Ltd./ | 10.49 |
| | & Telmisartan | contains: | | M/s Intas Pharmaceuticals | |
| | Tablets | Bisoprolol Fumarate IP 2.5 mg | | Ltd. | |
| | | Telmisartan IP 40 mg | | | |
+-----+-------------------------+------------------------------------------------------------------------------------+----------+-----------------------------------+-------------+
| 2 | Bisoprolol Fumarate | Each uncoated bilayered tablet | 1 Tablet | M/s Windlas Biotech Ltd./ | 12.09 |
| | & Telmisartan | contains: | | M/s Intas Pharmaceuticals | |
| | Tablets | Bisoprolol Fumarate IP 5 mg | | Ltd. | |
| | | Telmisartan IP 40 mg | | | |
+-----+-------------------------+------------------------------------------------------------------------------------+----------+-----------------------------------+-------------+
| 3 | Ceftriaxone & | Each vial contains: | 1 vial | M/s Innova Captab Ltd./ | 65.30 |
| | Sulbactam for | Ceftriaxone Sodium IP Eq. to | | M/s Dr. Reddys | |
| | Injection | Ceftriaxone 250 mg | | Laboratories Ltd. | |
+-----+-------------------------+------------------------------------------------------------------------------------+----------+-----------------------------------+-------------+
| 4 | Ceftriaxone & | Sulbactam Sodium IP Eq. to | 1 vial | M/s Innova Captab Ltd./ | 104.32 |
| | Sulbactam for | Sulbactam 125 mg | | M/s Dr. Reddys | |
| | Injection | Each vial contains: | | Laboratories Ltd. | |
| | | Ceftriaxone 500 mg | | | |
| | | Ceftriaxone Sodium IP Eq. to | | | |
| | | Sulbactam Sodium IP Eq. to | | | |
| | | Sulbactam 250 mg | | | |
+-----+-------------------------+------------------------------------------------------------------------------------+----------+-----------------------------------+-------------+
| 5 | Ceftriaxone, | Each vial contains: | 1 vial | M/s Gufic Biosciences Ltd./ | 567.13 |
| | Disodium Edetate & | Ceftriaxone Sodium IP (Sterile) | | M/s Criticare Division LLP | |
| | Sulbactam powder | Eq. to Ceftriaxone 1000 mg | | | |
| | for solution for | Disodium Edetate IP 37 mg | | | |
| | infusion | Sulbactam Sodium IP (Sterile) | | | |
| | | Eq. to Sulbactam 500 mg | | | |
+-----+-------------------------+------------------------------------------------------------------------------------+----------+-----------------------------------+-------------+
| 6 | Ceftriaxone, | Each vial contains: | 1 vial | M/s Gufic Biosciences Ltd./ | 1140.26 |
| | Disodium Edetate & | Ceftriaxone Sodium IP (Sterile) | | M/s Criticare Division LLP | |
| | Sulbactam powder | Eq. to Ceftriaxone 2000 mg | | | |
| | for solution for | Disodium Edetate IP 74 mg | | | |
| | infusion | Sulbactam Sodium IP (Sterile) | | | |
| | | Eq. to Sulbactam 1000 mg | | | |
+-----+-------------------------+------------------------------------------------------------------------------------+----------+-----------------------------------+-------------+
| 7 | Levocetirizine | Each 5 ml of Syrup contains: | 1 ml | M/s East African (I) | 1.48 |
| | Dihydrochloride & | Levocetirizine Dihydrochloride | | Overseas / M/s SRK | |
| | Montelukast | IP 2.5 mg | | Puremed LLP | |
| | Sodium Syrup | Montelukast Sodium IP | | | |
| | | Eq. to Montelukast 4 mg | | | |
+-----+-------------------------+------------------------------------------------------------------------------------+----------+-----------------------------------+-------------+
| 8 | Telmisartan & | Each uncoated bilayered tablet | 1 Tablet | M/s Unison Pharmaceuticals | 16.00 |
| | Amlodipine Tablets | contains: | | Pvt. Ltd. | |
| | | Telmisartan IP 80 mg | | | |
| | | Amlodipine Besylate IP eq. to | | | |
| | | Amlodipine 5 mg | | | |
+-----+-------------------------+------------------------------------------------------------------------------------+----------+-----------------------------------+-------------+
| 9 | Telmisartan & | Each uncoated bilayered tablet | 1 Tablet | M/s Swiss Garnier Life | 7.52 |
| | Hydrochlorothiazide | contains: | | Sciences / | |
| | Tablets | Telmisartan IP 40 mg | | M/s SRK Puremed LLP | |
| | | Hydrochlorothiazide IP 12.5 mg | | | |
+-----+-------------------------+------------------------------------------------------------------------------------+----------+-----------------------------------+-------------+
| 10 | Cefixime & | Each 5ml of reconstituted | 1 ml | M/s Prosperity Drugs | 1.74 |
| | Ofloxacin Oral | suspension contains: Cefixime | | Private Limited/ M/s Cachet | |
| | Suspension | trihydrate IP eq to Cefixime | | Pharmaceuticals Pvt. Ltd. | |
| | | anhydrous 50mg | | | |
| | | Ofloxacin IP 50mg | | | |
+-----+-------------------------+------------------------------------------------------------------------------------+----------+-----------------------------------+-------------+
| 11 | Teneligliptin, | Each film-coated bilayer | 1 Tablet | M/s Synokem Lifesciences | 12.15 |
| | Dapagliflozin, | tablet contains: Teneligliptin | | Pvt. Ltd / | |
| | Metformin | Hydrobromide Hydrate IP eq. to | | M/s Glenmark | |
| | (Sustained Release) | Teneligliptin 20 mg | | Pharmaceuticals Ltd. | |
| | Tablets | Dapagliflozin Propanediol | | | |
| | | Monohydrate eq. to | | | |
| | | Dapagliflozin 10 mg | | | |
| | | Metformin Hydrochloride IP 500 | | | |
| | | mg (As Sustained Release) | | | |
+-----+-------------------------+------------------------------------------------------------------------------------+----------+-----------------------------------+-------------+
Notes:
(a) The manufacturer of above-mentioned formulations i.e., "new drug" under paragraph 2(1)(u) of the DPCO,
2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification
as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller
and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business
in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned
above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under
DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt.
under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e.
the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing
companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification
and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit
the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the
Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with
the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in
Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength
for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5)
thereof, if any, issued prior to this notification, stand(s) superseded.
[PN/272/140/2025/F/F. No. 8(140)/2025/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Dy. Director
Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054.